Document is current

Any future updates will be listed below

A comparative health economic evaluation of venetoclax in combination with obinutuzumab versus Chlorambucil in combination with obinutuzumab as first-line treatment for chronic lymphocytic leukemia in China: a cost-effectiveness analysis

Crossref DOI link: https://doi.org/10.1186/s12962-025-00705-w

Published Online: 2026-01-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark